Financhill
Sell
28

AMGN Quote, Financials, Valuation and Earnings

Last price:
$295.07
Seasonality move :
3.01%
Day range:
$292.63 - $296.20
52-week range:
$253.30 - $346.85
Dividend yield:
3.05%
P/E ratio:
39.08x
P/S ratio:
4.77x
P/B ratio:
26.99x
Volume:
2.4M
Avg. volume:
3.2M
1-year change:
0.21%
Market cap:
$158.6B
Revenue:
$33.4B
EPS (TTM):
$7.55

Price Performance History

Performance vs. Valuation Benchmarks

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Competitors

Company Revenue Forecast Earnings Forecast Revenue Growth Forecast Earnings Growth Forecast Analyst Price Target Median
AMGN
Amgen
$8.9B $5.08 8.64% 257.4% $316.70
ABBV
AbbVie
$14.8B $2.12 5% 227.38% $204.90
LLY
Eli Lilly and
$13.4B $5.07 45.67% 89.53% $981.47
MRK
Merck &
$15.5B $1.67 -0.23% 13.87% $116.38
PFE
Pfizer
$17.3B $0.46 -3.38% 29% $31.18
VKTX
Viking Therapeutics
-- -$0.27 -- -25.22% $99.13
Company Price Analyst Target Market Cap P/E Ratio Dividend per Share Dividend Yield Price / LTM Sales
AMGN
Amgen
$295.06 $316.70 $158.6B 39.08x $2.25 3.05% 4.77x
ABBV
AbbVie
$193.00 $204.90 $341.1B 80.42x $1.64 3.26% 6.07x
LLY
Eli Lilly and
$872.97 $981.47 $785.1B 74.55x $1.30 0.6% 17.52x
MRK
Merck &
$85.67 $116.38 $216.7B 12.73x $0.81 3.64% 3.39x
PFE
Pfizer
$25.47 $31.18 $144.3B 18.06x $0.43 6.64% 2.28x
VKTX
Viking Therapeutics
$29.32 $99.13 $3.3B -- $0.00 0% --
Company Total Debt / Total Capital Beta Debt to Equity Quick Ratio
AMGN
Amgen
91.09% 0.218 42.9% 0.81x
ABBV
AbbVie
92.18% 0.524 -- 0.44x
LLY
Eli Lilly and
68.61% 1.194 -- 0.63x
MRK
Merck &
46.15% 0.628 -- 0.88x
PFE
Pfizer
41.92% 0.484 -- 0.64x
VKTX
Viking Therapeutics
-- 5.815 -- --
Company Gross Profit Operating Income Return on Invested Capital Return on Common Equity EBIT Margin Free Cash Flow
AMGN
Amgen
$6B $2.3B 5.97% 66.87% 16.83% $5.5B
ABBV
AbbVie
$10.7B -$1.5B 5.58% 58.92% -9.87% $5.2B
LLY
Eli Lilly and
$11.1B $5.7B 25.96% 66.4% 41.99% -$458.9M
MRK
Merck &
$11.8B $4.3B 21.98% 29.26% 27.82% $8.5B
PFE
Pfizer
$11.9B $3.2B 5.04% 4.63% 4.1% $6.1B
VKTX
Viking Therapeutics
-- -$46.2M -- -- -- -$22M

Amgen vs. Competitors

  • Which has Higher Returns AMGN or ABBV?

    AbbVie has a net margin of 6.9% compared to Amgen's net margin of -0.15%. Amgen's return on equity of 66.87% beat AbbVie's return on equity of 58.92%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    65.75% $1.16 $66B
    ABBV
    AbbVie
    70.89% -$0.02 $77.2B
  • What do Analysts Say About AMGN or ABBV?

    Amgen has a consensus price target of $316.70, signalling upside risk potential of 7.33%. On the other hand AbbVie has an analysts' consensus of $204.90 which suggests that it could grow by 6.16%. Given that Amgen has higher upside potential than AbbVie, analysts believe Amgen is more attractive than AbbVie.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    9 15 2
    ABBV
    AbbVie
    12 10 0
  • Is AMGN or ABBV More Risky?

    Amgen has a beta of 0.559, which suggesting that the stock is 44.064% less volatile than S&P 500. In comparison AbbVie has a beta of 0.579, suggesting its less volatile than the S&P 500 by 42.122%.

  • Which is a Better Dividend Stock AMGN or ABBV?

    Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.05%. AbbVie offers a yield of 3.26% to investors and pays a quarterly dividend of $1.64 per share. Amgen pays -- of its earnings as a dividend. AbbVie pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or ABBV?

    Amgen quarterly revenues are $9.1B, which are smaller than AbbVie quarterly revenues of $15.1B. Amgen's net income of $627M is higher than AbbVie's net income of -$22M. Notably, Amgen's price-to-earnings ratio is 39.08x while AbbVie's PE ratio is 80.42x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.77x versus 6.07x for AbbVie. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.77x 39.08x $9.1B $627M
    ABBV
    AbbVie
    6.07x 80.42x $15.1B -$22M
  • Which has Higher Returns AMGN or LLY?

    Eli Lilly and has a net margin of 6.9% compared to Amgen's net margin of 32.59%. Amgen's return on equity of 66.87% beat Eli Lilly and's return on equity of 66.4%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    65.75% $1.16 $66B
    LLY
    Eli Lilly and
    82.24% $4.88 $45.4B
  • What do Analysts Say About AMGN or LLY?

    Amgen has a consensus price target of $316.70, signalling upside risk potential of 7.33%. On the other hand Eli Lilly and has an analysts' consensus of $981.47 which suggests that it could grow by 12.43%. Given that Eli Lilly and has higher upside potential than Amgen, analysts believe Eli Lilly and is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    9 15 2
    LLY
    Eli Lilly and
    15 6 0
  • Is AMGN or LLY More Risky?

    Amgen has a beta of 0.559, which suggesting that the stock is 44.064% less volatile than S&P 500. In comparison Eli Lilly and has a beta of 0.416, suggesting its less volatile than the S&P 500 by 58.369%.

  • Which is a Better Dividend Stock AMGN or LLY?

    Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.05%. Eli Lilly and offers a yield of 0.6% to investors and pays a quarterly dividend of $1.30 per share. Amgen pays -- of its earnings as a dividend. Eli Lilly and pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or LLY?

    Amgen quarterly revenues are $9.1B, which are smaller than Eli Lilly and quarterly revenues of $13.5B. Amgen's net income of $627M is lower than Eli Lilly and's net income of $4.4B. Notably, Amgen's price-to-earnings ratio is 39.08x while Eli Lilly and's PE ratio is 74.55x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.77x versus 17.52x for Eli Lilly and. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.77x 39.08x $9.1B $627M
    LLY
    Eli Lilly and
    17.52x 74.55x $13.5B $4.4B
  • Which has Higher Returns AMGN or MRK?

    Merck & has a net margin of 6.9% compared to Amgen's net margin of 23.96%. Amgen's return on equity of 66.87% beat Merck &'s return on equity of 29.26%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    65.75% $1.16 $66B
    MRK
    Merck &
    75.5% $1.48 $82.7B
  • What do Analysts Say About AMGN or MRK?

    Amgen has a consensus price target of $316.70, signalling upside risk potential of 7.33%. On the other hand Merck & has an analysts' consensus of $116.38 which suggests that it could grow by 35.85%. Given that Merck & has higher upside potential than Amgen, analysts believe Merck & is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    9 15 2
    MRK
    Merck &
    13 9 0
  • Is AMGN or MRK More Risky?

    Amgen has a beta of 0.559, which suggesting that the stock is 44.064% less volatile than S&P 500. In comparison Merck & has a beta of 0.383, suggesting its less volatile than the S&P 500 by 61.682%.

  • Which is a Better Dividend Stock AMGN or MRK?

    Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.05%. Merck & offers a yield of 3.64% to investors and pays a quarterly dividend of $0.81 per share. Amgen pays -- of its earnings as a dividend. Merck & pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or MRK?

    Amgen quarterly revenues are $9.1B, which are smaller than Merck & quarterly revenues of $15.6B. Amgen's net income of $627M is lower than Merck &'s net income of $3.7B. Notably, Amgen's price-to-earnings ratio is 39.08x while Merck &'s PE ratio is 12.73x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.77x versus 3.39x for Merck &. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.77x 39.08x $9.1B $627M
    MRK
    Merck &
    3.39x 12.73x $15.6B $3.7B
  • Which has Higher Returns AMGN or PFE?

    Pfizer has a net margin of 6.9% compared to Amgen's net margin of 2.31%. Amgen's return on equity of 66.87% beat Pfizer's return on equity of 4.63%.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    65.75% $1.16 $66B
    PFE
    Pfizer
    66.73% $0.07 $159.2B
  • What do Analysts Say About AMGN or PFE?

    Amgen has a consensus price target of $316.70, signalling upside risk potential of 7.33%. On the other hand Pfizer has an analysts' consensus of $31.18 which suggests that it could grow by 22.4%. Given that Pfizer has higher upside potential than Amgen, analysts believe Pfizer is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    9 15 2
    PFE
    Pfizer
    7 13 1
  • Is AMGN or PFE More Risky?

    Amgen has a beta of 0.559, which suggesting that the stock is 44.064% less volatile than S&P 500. In comparison Pfizer has a beta of 0.642, suggesting its less volatile than the S&P 500 by 35.808%.

  • Which is a Better Dividend Stock AMGN or PFE?

    Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.05%. Pfizer offers a yield of 6.64% to investors and pays a quarterly dividend of $0.43 per share. Amgen pays -- of its earnings as a dividend. Pfizer pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or PFE?

    Amgen quarterly revenues are $9.1B, which are smaller than Pfizer quarterly revenues of $17.8B. Amgen's net income of $627M is higher than Pfizer's net income of $410M. Notably, Amgen's price-to-earnings ratio is 39.08x while Pfizer's PE ratio is 18.06x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.77x versus 2.28x for Pfizer. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.77x 39.08x $9.1B $627M
    PFE
    Pfizer
    2.28x 18.06x $17.8B $410M
  • Which has Higher Returns AMGN or VKTX?

    Viking Therapeutics has a net margin of 6.9% compared to Amgen's net margin of --. Amgen's return on equity of 66.87% beat Viking Therapeutics's return on equity of --.

    Company Gross Margin Earnings Per Share Invested Capital
    AMGN
    Amgen
    65.75% $1.16 $66B
    VKTX
    Viking Therapeutics
    -- -$0.32 --
  • What do Analysts Say About AMGN or VKTX?

    Amgen has a consensus price target of $316.70, signalling upside risk potential of 7.33%. On the other hand Viking Therapeutics has an analysts' consensus of $99.13 which suggests that it could grow by 238.08%. Given that Viking Therapeutics has higher upside potential than Amgen, analysts believe Viking Therapeutics is more attractive than Amgen.

    Company Buy Ratings Hold Ratings Sell Ratings
    AMGN
    Amgen
    9 15 2
    VKTX
    Viking Therapeutics
    9 1 0
  • Is AMGN or VKTX More Risky?

    Amgen has a beta of 0.559, which suggesting that the stock is 44.064% less volatile than S&P 500. In comparison Viking Therapeutics has a beta of 0.900, suggesting its less volatile than the S&P 500 by 10.034%.

  • Which is a Better Dividend Stock AMGN or VKTX?

    Amgen has a quarterly dividend of $2.25 per share corresponding to a yield of 3.05%. Viking Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Amgen pays -- of its earnings as a dividend. Viking Therapeutics pays out -- of its earnings as a dividend.

  • Which has Better Financial Ratios AMGN or VKTX?

    Amgen quarterly revenues are $9.1B, which are larger than Viking Therapeutics quarterly revenues of --. Amgen's net income of $627M is higher than Viking Therapeutics's net income of -$35.4M. Notably, Amgen's price-to-earnings ratio is 39.08x while Viking Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Amgen is 4.77x versus -- for Viking Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

    Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income
    AMGN
    Amgen
    4.77x 39.08x $9.1B $627M
    VKTX
    Viking Therapeutics
    -- -- -- -$35.4M

SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS

GET BETTER TRADE IDEAS

Popular

What Will Palantir Stock Be Worth in 2030?
What Will Palantir Stock Be Worth in 2030?

Palantir Technologies (NYSE: PLTR) has emerged from a growth slowdown…

Is Rollins Stock a Buy, Sell or Hold?
Is Rollins Stock a Buy, Sell or Hold?

Pest control giant Rollins (NYSE:ROL) is the parent company of…

Why Did Bill Ackman Buy Uber?
Why Did Bill Ackman Buy Uber?

In early 2025, billionaire investor Bill Ackman, CEO of Pershing…

Stock Ideas

Buy
61
Is AAPL Stock a Buy?

Market Cap: $3.6T
P/E Ratio: 39x

Buy
54
Is NVDA Stock a Buy?

Market Cap: $3.2T
P/E Ratio: 110x

Sell
43
Is MSFT Stock a Buy?

Market Cap: $3T
P/E Ratio: 35x

Alerts

Buy
58
UPST alert for Feb 13

Upstart Holdings [UPST] is up 31.82% over the past day.

Buy
79
CFLT alert for Feb 13

Confluent [CFLT] is up 24.92% over the past day.

Buy
52
BL alert for Feb 13

BlackLine [BL] is down 18.03% over the past day.

THE #1 STOCK ANALYSIS TOOL
TO MAKE SMARTER BUY AND SELL DECISIONS

Show me the best stock